Alembic Pharmaceuticals has informed that the Company has successfully completed the United States Food and Drug Administration (USFDA) inspection for its API-III Facility located at Karakhadi. This was a scheduled GMP inspection and was successfully completed without any Form 483 observation. The inspection was conducted from 17th March, 2025 to 21st March, 2025.
The above information is a part of company’s filings submitted to BSE.